What is Soft Tissue Sarcoma and How Common is It?

Soft tissue sarcoma is a type of cancer that usually occurs in the soft tissues that surround, connect, or support the structures and organs of the body. These tissues include muscles, joints, tendons, fat, blood vessels, nerves, and surrounding tissues. The incidence of soft tissue sarcoma is not high — the American Cancer Society estimates that by 2023, about 13,400 adults and children will be diagnosed with soft tissue sarcoma. Soft tissue sarcomas account for 1% of all adult cancers, 7% of all cancers in children under 15 years old, and 3% of all cancers in children 14 years and younger.

How is Soft Tissue Sarcoma Treated?

The treatment of soft tissue sarcoma usually depends on the cancer’s type, location, and stage. Soft tissue sarcoma detected early can be surgically removed and further controlled with radiation and chemotherapy. For advanced or metastatic soft tissue sarcoma, chemotherapy is a common treatment method, but these patients usually have poor treatment outcomes.

In recent years, the introduction of targeted therapy and immunotherapy has brought new breakthroughs to the treatment of soft tissue sarcoma. Certain targeted drugs can address specific genetic mutations in soft tissue sarcoma cells, thereby increasing the precision of treatment.

Surgical Treatment

Surgery is the main treatment method for soft tissue sarcoma. The success rate of surgery is often closely related to the experience of the doctor performing the surgery. Experienced sarcoma treatment specialists usually use the most advanced and minimally invasive techniques to perform surgery. Chemotherapy or radiotherapy may be combined after surgery for further treatment.

Limb-sparing surgery is a special surgical method that can avoid limb amputation for most patients. Patients do not need to remove arms or legs to treat sarcoma, and surgery is usually combined with radiotherapy after the procedure.

Chemotherapy

Chemotherapy can be used as a primary treatment for soft tissue sarcoma or combined with surgery or radiotherapy. Chemotherapy typically involves a combination of two or more chemotherapy drugs. Sometimes, limb perfusion chemotherapy (a type of localized chemotherapy) is also used to provide more concentrated drug treatment to the limb.

Radiation Therapy

Radiation therapy is not usually the main treatment for soft tissue sarcoma, but it is used before surgery to shrink tumors or after surgery to eliminate residual cancer cells. If the patient cannot undergo surgery, radiation therapy may also help relieve pain and other symptoms.

Radiation therapy techniques include:

• Brachytherapy: Implanting radioactive seeds near the tumor

• 3D Conformal Radiation Therapy: Precisely targeting the tumor with multiple radiation beams

• Intensity-Modulated Radiation Therapy (IMRT): Adjusting treatment according to the specific shape of the tumor

• Proton Therapy: Using protons to precisely target the tumor, effectively protecting surrounding healthy tissue

Proton Therapy

Proton therapy delivers high-dose radiation precisely to the tumor site using a proton beam, minimizing damage to healthy tissues and vital organs. This treatment can provide better cancer control outcomes and has less impact on the body, making it suitable for some patients.

Targeted Therapy (Precision Medicine)

Targeted therapy inhibits the growth or spread of cancer cells by interfering with specific molecules needed for tumor growth, slowing the progression of cancer. Targeted therapy is directed at specific molecules on or within cancer cells that are produced by cancer genes or the cancer cells themselves. Doctors may use genomic or molecular analyses to select the most suitable targeted therapy to effectively combat cancer.

Can Soft Tissue Sarcoma Patients Be Cured?

According to NIH reports, small low-grade tumors, especially those in the trunk or limbs, can usually be cured with surgery alone. High-grade sarcomas have a higher rate of local treatment failure and a greater potential for metastasis.

Factors associated with poor prognosis in adult soft tissue sarcoma include:

• Age over 60 years

• Tumor size (e.g., maximum dimension greater than 5 cm; the impact varies with different sarcoma subtypes)

• High histological grade of the tumor (including histological specific differentiation, mitotic rate, and extent of tumor necrosis)

• Advanced stage tumor pathology at diagnosis

• Positive tumor margins after surgery

Advantages and Latest Developments in Treating Soft Tissue Sarcoma in China

The advantages of sarcoma treatment at China’s leading cancer centers include:

Top cancer centers in China (such as the National Cancer Center China and Cancer Hospital of CAMS) adopt a Multidisciplinary Team (MDT) collaboration model, integrating experts from fields such as surgery, medical oncology, radiation oncology, pathology, and radiology to collaboratively develop the optimal treatment plan for each patient’s condition.

Leading cancer centers in China have extensive Phase I–III clinical trial programs, allowing patients early access to the latest global research drugs and treatment methods.

The latest advancements in sarcoma treatment in China include:

• Immunotherapy: China’s leading centers have introduced immunotherapy as a new option for treating advanced sarcoma, particularly for specific types of soft tissue sarcoma. The National Cancer Center China has been conducting studies on adaptive NK cells combined with lymphocyte-clearing chemotherapy for certain types of sarcomas.

• Precision Radiotherapy: High-precision radiotherapy offers sarcoma patients accurate treatment, minimizing damage to surrounding healthy tissue. Ongoing research investigates whether different radiotherapy methods might provide additional benefits, including whether pre-surgical radiotherapy is safe and effective for treating soft tissue sarcoma.

• Targeted Therapy: Based on the molecular characteristics of different types of sarcoma, targeted therapy drugs have received positive feedback in clinical trials. For example, the drug Selinexor has shown efficacy in soft tissue sarcoma patients by significantly delaying tumor progression, especially in certain resistant types.

Leading Hospitals and Experts in China for Treating Soft Tissue Sarcoma

1. National Cancer Center China / Cancer Hospital of CAMS

• Location: Beijing, China

• Advantages: One of the most renowned cancer hospitals in China, with a dedicated sarcoma department that is among the leading institutions nationally for sarcoma treatment.

Introduction of Expert:

Dr. Lin (alias) is a renowned sarcoma expert at the National Cancer Center China, specializing in the diagnosis and treatment of sarcoma with extensive experience in soft tissue sarcomas and osteosarcomas. His research focuses on targeted therapies, immunotherapy, and clinical trials of new drugs for sarcomas. He is dedicated to improving patients’ cure rates and quality of life through personalized treatment plans.

2. Fudan University Shanghai Cancer Center (FUSCC)

• Location: Shanghai, China

• Strengths: The center specializes in clinical trials and cutting-edge therapies, committed to providing sarcoma patients with innovative treatment options and molecular profiling.

Pain Points for International Sarcoma Patients

For families facing a major disease diagnosis, accessing advanced therapies often seems out of reach.

Challenge 1: Difficulty in Choosing Treatment Options

Patients may lack understanding of various treatment methods (such as medication, surgery), making it difficult to make informed decisions.

Challenge 2: High Medical Costs

Sarcomas often require long-term treatment, which can lead to significant financial pressure on patients, not including long-distance travel, accommodation, and living expenses. Additionally, 95% of international patients do not have insurance to cover these costs.

Challenge 3: Language and Cultural Barriers

International patients may face challenges with language communication and cultural differences when seeking medical treatment abroad, affecting treatment outcomes.

Challenge 4: Need for Long-Term Stay or Commuting

Sarcoma treatment is a long-term process, and periodic remission does not equate to long-term remission. Some patients, once they seek treatment abroad, face a long stay or tiring commutes between two countries.

Is there a way to help patients reduce this burden? Yes, indeed there is.

How ChinaCureLink Helps You Access Sarcoma Treatment in China — Without the Guesswork

Knowing that sarcoma treatment exists in China is one thing. Getting there safely, affordably, and connected to the right hospital is another. This is exactly the gap ChinaCureLink was built to close.

Founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, ChinaCureLink is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific. Contact us below for free medical record review.

Southeast Asian Sarcoma Patient: Remote Video Consultation and Clinical Trial Enrollment

A 56-year-old Indonesian male patient (Mr. Budi, pseudonym) was diagnosed with advanced dedifferentiated liposarcoma domestically, with lung metastases. He underwent partial surgery and chemotherapy but relapsed quickly, and the tumor showed resistance to standard chemotherapy regimens (doxorubicin and ifosfamide).

In this situation, the patient and his family found ChinaCureLink — a cross-border medical service organization with 9 years of overseas medical service experience and a patient satisfaction rate of 95%.

Video Consultation and Initial Diagnosis

With the assistance of ChinaCureLink, Mr. Budi had a consultation through remote video with sarcoma specialist Dr. Liu (alias) at the National Cancer Center China in Beijing.

Dr. Lin provided the patient with a personalized treatment plan, including the latest immunotherapy options and precision radiotherapy, and recommended opportunities to participate in related clinical trials. After receiving the treatment plan, the patient’s tumor was effectively controlled domestically, and after stabilizing his condition, he traveled to the National Cancer Center China to participate in the clinical trials Dr. Lin recommended.

On-Site Consultation at National Cancer Center China

At the National Cancer Center China, led by Dr. Lin (alias), Mr. Budi received a comprehensive treatment plan:

• Personalized Targeted Therapy: Based on genetic testing of the tumor, the patient was selected for a clinical trial of a targeted drug for MDM2 gene amplification, using an experimental medication.

• Local Radiotherapy: Prior to targeted therapy, precise radiotherapy was applied to the primary tumor site to shrink the tumor and relieve pain.

• Supportive Therapy: To enhance immune function, the patient also received immunomodulatory therapy to mitigate the side effects of targeted drugs.

After 6 months of treatment, the patient’s lung lesions reduced by over 40%, and the primary tumor remained stable. The patient was able to resume daily life and continue long-term follow-up treatment.

Patient Testimonial

The patient and his family expressed high appreciation and gratitude for Dr. Lin’s consultation and face-to-face treatment. They believe that this remote consultation and medical visit provided them with new hope and direction for treatment, allowing Mr. Budi to have a dignified and quality life after the cancer diagnosis.

The family highly acknowledges ChinaCureLink's professional services and volunteered to recommend the service to well-known local hospitals in Indonesia, helping more patients connect with world-class medical expertise.

How ChinaCureLink Supports Your Cancer Treatment Journey

ChinaCureLink bridges the gap between you and the best cancer experts, whether you’re seeking a virtual consultation or planning your medical travel. Our services include:

• Connecting you with leading sarcoma doctors at National Cancer Center China, Fudan University Shanghai Cancer Center (FUSCC), and other top hospitals

• Assisting with both written and video second opinions, as well as on-site appointments for in-person treatment

• A more efficient appointment process compared to contacting the hospital’s international department directly:

• Second opinions can be completed within 1–2 weeks

• On-site appointments can be arranged within 3–4 weeks

• Coordinating comprehensive support for travel logistics, including visa assistance, accommodation arrangements, and interpreter services

• For on-site appointments, providing additional daily life translation support to help you feel comfortable throughout your stay

• Providing continuous care coordination to ensure smooth communication between your local doctors and specialists, so your treatment plan is clear and seamless

Conclusion

Facing sarcoma can be daunting, but with ChinaCureLink, you don’t have to navigate it alone. Whether you start with an online second opinion or plan a full medical trip, you gain access to the most advanced treatments and compassionate care.

You can take charge of your treatment with expert guidance, clear options, and the reassurance that sarcoma doesn’t stand a chance against the power of world-class cancer treatment.

About China Curelink

China Curelink helps patients across Southeast Asia — including Indonesia, Malaysia, the Philippines, Vietnam, and Thailand — access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.

We connect patients directly with China's top 5 cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team that understands both the medical and cultural needs of Southeast Asian patients.

China Curelink is proudly affiliated with Medebound HEALTH— an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia Pacific, Medebound HEALTH brings the same standard of expert care coordination to every patient we serve.

This article is for informational purposes only and does not constitute medical advice. All treatment decisions should be made in consultation with a qualified oncologist who has reviewed your complete medical history and current diagnostic information.